Welcome!

News Feed Item

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

NEW YORK, March 19, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability
http://www.reportlinker.com/p02052296/Epilepsy-Therapeutics-in-Asia-Pacific-Markets-to-2019---Treatment-Options-Enhanced-As-Novel-Next-Generation-AEDs-Show-Improved-Safety-and-Tolerability.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability", which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019. The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic scope. Conversely, the growth of the market in APAC region could face the restricting influence of prescribing patterns that give preference to older generation drugs and also due to generic competition as a result of key patent expiries.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in anti-epileptics in the four APAC markets of Australia, China, India and Japan. The report includes -
- A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options
- In-depth analysis of major marketed products covering product performance, product life-cycle and a heat map depicting comparative analysis of safety and efficacy parameters
- A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target.
- Additional clinical trial analysis by Phase, trial size, trial duration and program failure rate for each molecule type and mechanism of action
- Multi-scenario forecasts of the epilepsy market from 2012 to 2019 in the four APAC regions
- In-depth analysis of licensing and co-development agreements and an overview of key agreements that could impact growth trends
- Key drivers and restraints that have had and are expected to have a significant impact upon the market

Reasons to buy

The report will enhance your decision-making capability by allowing you to -
- Align your product portfolio to markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise effective, tailored strategies for each country through the understanding of key drivers and barriers in the anti-epileptic drugs market
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
1 Table of Contents
1 Table of Contents 5

1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Disease Overview 8
2.2 Epidemiology 8
2.3 Symptoms 9
2.4 Etiology 10
2.5 Pathophysiology 10
2.6 Co-morbidities/Complications 11
2.7 Diagnosis 11
2.8 Prognosis 11
2.9 Treatment Efficacy 11
2.10 Treatment Options 12
2.10.1 Ion Channel Modulators 12
2.10.2 GABA-ergic Facilitation 12
2.10.3 Excitatory Amino Acid Inhibitors 12
2.10.4 Synaptic Modulators 12
2.11 Non-pharmacological Management 13
2.11.1 Lobectomy and Lesionectomy 13
2.11.2 Ketogenic Diet and Modified Atkins Diet 13

2.11.3 Vagus Nerve Stimulation 13
3 Epilepsy Therapeutic Landscape 14
3.1 Overview 14
3.2 Lyrica (pregabalin) 14
3.3 Lamictal (lamotrigine) 15
3.4 Keppra (levetiracetam) 16
3.5 Zonegran (zonisamide) 18
3.6 Vimpat (lacosamide) 19
3.7 Aptiom/Zebinix (eslicarbazepine acetate) 21
3.8 Fycompa (perampanel) 21
3.9 Trobalt/Potiga (ezogabine/retigabine) 22
3.10 Banzel/Inovelon (rufinamide) 23
3.11 Comparative Efficacy and Safety of Marketed Products 23
4 Pipeline for Epilepsy Therapeutics 26
4.1 Overall Pipeline 26
4.2 Pipeline by Mechanism of Action 28
4.3 Clinical Trials 29
4.3.1 Failure Rate 29
4.3.2 Patient Enrolment and Clinical Trial Size 31
4.3.3 Clinical Trial Duration 32
4.4 Promising Pipeline Candidates 33
4.4.1 Brivaracetam – UCB 33
4.4.2 Ganaxolone – Marinus Pharmaceuticals 33
5 Epilepsy Therapeutics Market Forecast to 2019 34
5.1 Geographical Markets 34
5.1.1 Key Asia-Pacific Markets 34
5.1.2 China 36

5.1.3 India 38
5.1.4 Japan 40
5.1.5 Australia 42
5.2 Drivers and Barriers 44
5.2.1 Drivers 44
5.2.2 Barriers 44
6 Deals and Strategic Consolidations 45
6.1 Deals Analysis 45
6.2 Research and Development Co-development Agreements 47
6.3 Research and Development Licensing Agreements 48
7 Appendix 50
7.1 Abbreviations 50
7.2 References 51
7.3 References for Heat Maps 55
7.4 Pipeline Products by Phase 56
7.4.1 Discovery 56
7.4.2 Preclinical 57
7.4.3 IND-filed and Phase 0 58
7.4.4 Phase I 58
7.4.5 Phase II 59
7.4.6 Phase III 60
7.4.7 Pre-registration 60
7.5 Market Forecasting Data Tables to 2019 61
7.5.1 Asia-Pacific 61
7.5.2 China 61
7.5.3 India 61
7.5.4 Japan 62
7.5.5 Australia 62

7.6 Research Methodology 62
7.6.1 Coverage 62
7.6.2 Secondary Research 63
7.6.3 Primary Research 63
7.6.4 Therapeutic Landscape 63
7.6.5 Geographical Landscape 66
7.6.6 Pipeline Analysis 66
7.7 Expert Panel Validation 66
7.8 Contact Us 66
7.9 Disclaimer 66

1.1 List of Tables
Table 1: Epilepsy Therapeutics, Global, Types of Seizures, 2013 8
Table 2: Epilepsy Therapeutics, Heat Maps for Efficacy and Safety of Marketed Products, References 55
Table 3: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Discovery), 2013 56
Table 4: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Preclinical), 2013 57
Table 5: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013 58
Table 6: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase I), 2013 58
Table 7: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase II), 2013 59
Table 8: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Phase III), 2013 60
Table 9: Epilepsy Therapeutics, Global, Pharmaceutical Pipeline (Pre-registration), 2013 60
Table 10: Epilepsy Therapeutics, Asia-Pacific, Market Forecast, 2012–2019 61
Table 11: Epilepsy Therapeutics, China, Market Forecast, 2012–2019 61
Table 12: Epilepsy Therapeutics, India, Market Forecast, 2012–2019 61
Table 13: Epilepsy Therapeutics, Japan, Market Forecast, 2012–2019 62
Table 14: Epilepsy Therapeutics, Australia, Market Forecast, 2012–2019 62

1.2 List of Figures
Figure 1: Epilepsy Therapeutics, Epidemiology, Asia-Pacific, 2012 9
Figure 2: Epilepsy Therapeutics, Lyrica, Global, Revenue ($bn), 2013 15
Figure 3: Epilepsy Therapeutics, Lamictal, Global, Revenue ($m), 2009–2013 16
Figure 4: Epilepsy Therapeutics, Keppra, Global, Revenue ($bn), 2009–2013 17
Figure 5: Epilepsy Therapeutics, Zonegran, Global, Revenue ($m), 2009–2013 18
Figure 6: Epilepsy Therapeutics, Vimpat, Global, Revenue ($m), 2009–2013 20
Figure 7: Epilepsy Therapeutics, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2013 24
Figure 8: Epilepsy Therapeutics, Global, Overall Pipeline Analysis, 2013 27
Figure 9: Epilepsy Therapeutics, Global, Pipeline Analysis, by Mechanism of Action, 2013 28
Figure 10: Epilepsy Therapeutics, Global, Clinical Trial Failure Rate, 2013 30
Figure 11: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Size, 2013 31
Figure 12: Epilepsy Therapeutics, Global, Pipeline, Clinical Trial Duration, 2013 32
Figure 13: Epilepsy Therapeutics, Asia-Pacific, Market Size, 2012–2019 35
Figure 14: Epilepsy Therapeutics, China, Market Size, 2012–2019 37
Figure 15: Epilepsy Therapeutics, India, Market Size, 2012–2019 39
Figure 16: Epilepsy Therapeutics, Japan, Market Size, 2012–2019 41
Figure 17: Epilepsy Therapeutics, Australia, Market Size, 2012–2019 43
Figure 18: Epilepsy Therapeutics, Deals by Region, Value and Year, 2006–2013 45
Figure 19: Epilepsy Therapeutics, Deals by Molecule Type and Mechanism of Action, 2006–2013 46
Figure 20: Epilepsy Therapeutics, Co-development Deals, Territory, 2006–2013 47
Figure 21: Epilepsy Therapeutics, Licensing Deals, by Territory, 2006–2013 48
Figure 22: GBI Research Market Forecasting Model 65

To order this report: Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability
http://www.reportlinker.com/p02052296/Epilepsy-Therapeutics-in-Asia-Pacific-Markets-to-2019---Treatment-Options-Enhanced-As-Novel-Next-Generation-AEDs-Show-Improved-Safety-and-Tolerability.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Imagine having the ability to leverage all of your current technology and to be able to compose it into one resource pool. Now imagine, as your business grows, not having to deploy a complete new appliance to scale your infrastructure. Also imagine a true multi-cloud capability that allows live migration without any modification between cloud environments regardless of whether that cloud is your private cloud or your public AWS, Azure or Google instance. Now think of a world that is not locked i...
SYS-CON Events announced today that Auditwerx will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Auditwerx specializes in SOC 1, SOC 2, and SOC 3 attestation services throughout the U.S. and Canada. As a division of Carr, Riggs & Ingram (CRI), one of the top 20 largest CPA firms nationally, you can expect the resources, skills, and experience of a much larger firm combined with the accessibility and atten...
In his session at @ThingsExpo, Eric Lachapelle, CEO of the Professional Evaluation and Certification Board (PECB), will provide an overview of various initiatives to certifiy the security of connected devices and future trends in ensuring public trust of IoT. Eric Lachapelle is the Chief Executive Officer of the Professional Evaluation and Certification Board (PECB), an international certification body. His role is to help companies and individuals to achieve professional, accredited and worldw...
MongoDB Atlas leverages VPC peering for AWS, a service that allows multiple VPC networks to interact. This includes VPCs that belong to other AWS account holders. By performing cross account VPC peering, users ensure networks that host and communicate their data are secure. In his session at 20th Cloud Expo, Jay Gordon, a Developer Advocate at MongoDB, will explain how to properly architect your VPC using existing AWS tools and then peer with your MongoDB Atlas cluster. He'll discuss the secur...
Deep learning has been very successful in social sciences and specially areas where there is a lot of data. Trading is another field that can be viewed as social science with a lot of data. With the advent of Deep Learning and Big Data technologies for efficient computation, we are finally able to use the same methods in investment management as we would in face recognition or in making chat-bots. In his session at 20th Cloud Expo, Gaurav Chakravorty, co-founder and Head of Strategy Development ...
SYS-CON Events announced today that Linux Academy, the foremost online Linux and cloud training platform and community, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Linux Academy was founded on the belief that providing high-quality, in-depth training should be available at an affordable price. Industry leaders in quality training, provided services, and student certification passes, its goal is to c...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
In his session at Cloud Expo, Alan Winters, an entertainment executive/TV producer turned serial entrepreneur, will present a success story of an entrepreneur who has both suffered through and benefited from offshore development across multiple businesses: The smart choice, or how to select the right offshore development partner Warning signs, or how to minimize chances of making the wrong choice Collaboration, or how to establish the most effective work processes Budget control, or how to m...
"delaPlex is a software development company. We do team-based outsourcing development," explained Mark Rivers, COO and Co-founder of delaPlex Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From ...
SYS-CON Events announced today that Technologic Systems Inc., an embedded systems solutions company, will exhibit at SYS-CON's @ThingsExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Technologic Systems is an embedded systems company with headquarters in Fountain Hills, Arizona. They have been in business for 32 years, helping more than 8,000 OEM customers and building over a hundred COTS products that have never been discontinued. Technologic Systems’ pr...
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
What if you could build a web application that could support true web-scale traffic without having to ever provision or manage a single server? Sounds magical, and it is! In his session at 20th Cloud Expo, Chris Munns, Senior Developer Advocate for Serverless Applications at Amazon Web Services, will show how to build a serverless website that scales automatically using services like AWS Lambda, Amazon API Gateway, and Amazon S3. We will review several frameworks that can help you build serverle...
SYS-CON Events announced today that Loom Systems will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Founded in 2015, Loom Systems delivers an advanced AI solution to predict and prevent problems in the digital business. Loom stands alone in the industry as an AI analysis platform requiring no prior math knowledge from operators, leveraging the existing staff to succeed in the digital era. With offices in S...